IP Library › Granted Patent US 12,404,504
Granted Patent B2
US 12,404,504 · App. 17/339,607 · Granted Sep 2, 2025

Transposition of nucleic acids into eukaryotic genomes with a transposase from heliothis

Inventors: Jeremy Minshull (Los Altos, CA); Sridhar Govindarajan (Los Altos, CA); Maggie Lee (San Jose, CA)
Assignee: DNA TWOPOINTO INC.
C12N15/11C12N5/0602C12N9/1241C12Y207/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,504
App. No.
17/339,607
Granted
Sep 2, 2025
Kind
B2
Abstract

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

Claims (17)

1. A polynucleotide comprising an open reading frame encoding a transposase, the amino acid sequence of which is at least 90% identical to SEQ ID NO: 39, operably linked to a heterologous promoter, wherein the amino acid sequence comprises at least 2 mutations selected from S41V, L43S, V81E, V81P, D83S, V85L, P125S, Q126S, Q131R, Q131T, S136V, E140C, E140A, 1149C, N151Q, K152L, L153F, D155T, T162I, K169E, N212S, V238F, I239L, H241N, S264R, T268D, T268E, V280P, T297C, L299F, M300R, M305N, L312I, C316A, N322T, H357R, K360Q, K396R, K397S, Y421F, H430Y, A447N, A447D, A449S, A449V, V450I, K476L, R485K, V492A, Y495F, L507I, H512N, L585K, S589T, T595K and Q603K, relative to the sequence of SEQ ID NO: 39.

2. A polynucleotide comprising an open reading frame encoding a transposase operably linked to a heterologous promoter, wherein the amino acid sequence of the transposase is selected from SEQ ID NO: 131-490.

3. The polynucleotide of claim 1 , wherein the transposase can excise or transpose the transposon from SEQ ID NO: 66.

4. The polynucleotide of claim 3 , wherein the excision activity or transposition activity of the transposase is at least 2-fold higher than the activity of the wild type transposase set forth by SEQ ID NO: 39.

5. The polynucleotide of claim 1 , wherein the heterologous promoter is active in an in vitro transcription reaction.

6. The polynucleotide of claim 1 , wherein the heterologous promoter is active in a eukaryotic cell.

7. The polynucleotide of claim 6 , wherein the eukaryotic cell is a mammalian cell, optionally, wherein codons of the open reading frame are selected for expression in the mammalian cell.

8. The polynucleotide of claim 1 , wherein the open reading frame further encodes a nuclear localization sequence fused to the transposase.

9. The polynucleotide of claim 1 , wherein the open reading frame further encodes a heterologous DNA binding domain fused to the transposase.

10. The polynucleotide of claim 9 , wherein the heterologous DNA binding domain is derived from a Crispr Cas system, or a zinc finger protein, or a TALE nuclease.

11. An isolated mRNA encoding a transposase, the amino acid sequence of which is at least 90% identical with SEQ ID NO: 39, and wherein the mRNA sequence comprises at least 10 synonymous codon differences relative to SEQ ID NO: 1181, optionally selected for mammalian expression, wherein the amino acid sequence comprises at least 2 mutations selected from S41V, L43S, V81E, V81P, D83S, V85L, P125S, Q126S, Q131R, Q131T, S136V, E140C, E140A, 1149C, N151Q, K152L, L153F, D155T, T162I, K169E, N212S, V238F, I239L, H241N, S264R, T268D, T268E, V280P, T297C, L299F, M300R, M305N, L312I, C316A, N322T, H357R, K360Q, K396R, K397S, Y421F, H430Y, A447N, A447D, A449S, A449V, V450I, K476L, R485K, V492A, Y495F, L507I, H512N, L585K, S589T, T595K and Q603K, relative to the sequence of SEQ ID NO: 39.

12. A non-naturally occurring polynucleotide encoding a transposase comprising an amino acid sequence at least 90% identical to SEQ ID NO: 39 wherein the amino acid sequence comprises at least 2 mutations selected from S41V, L43S, V81E, V81P, D83S, V85L, P125S, Q126S, Q131R, Q131T, S136V, E140C, E140A, 1149C, N151Q, K152L, L153F, D155T, T162I, K169E, N212S, V238F, 1239L, H241N, S264R, T268D, T268E, V280P, T297C, L299F, M300R, M305N, L312I, C316A, N322T, H357R, K360Q, K396R, K397S, Y421F, H430Y, A447N, A447D, A449S, A449V, V450I, K476L, R485K V492A, Y495F, L507I, H512N, L585K, S589T, T595K and Q603K, relative to the sequence of SEQ ID NO: 39.

13. A non-naturally occurring transposase encoded by the polynucleotide of claim 1 .

14. The polynucleotide of claim 4 , wherein the excision activity or transposition activity of the transposase is 2 to 10 fold higher than the activity of the transposase of SEQ ID NO:39.

15. The polynucleotide of claim 1 , wherein the amino acid sequence comprises at least 4 mutations selected from S41V, L43S, V81E, V81P, D83S, V85L, P125S, Q126S, Q131R, Q131T, S136V, E140C, E140A, 1149C, N151Q, K152L, L153F, D155T, T162I, K169E, N212S, V238F, I239L, H241N, S264R, T268D, T268E, V280P, T297C, L299F, M300R, M305N, L312I, C316A, N322T, H357R, K360Q, K396R, K397S, Y421F, H430Y, A447N, A447D, A449S, A449V, V450I, K476L, R485K, V492A, Y495F, L507I, H512N, L585K, S589T, T595K and Q603K, relative to the sequence of SEQ ID NO: 39.

16. The isolated mRNA of claim 11 , wherein the amino acid sequence comprises at least 4 mutations selected from S41V, L43S, V81E, V81P, D83S, V85L, P125S, Q126S, Q131R, Q131T, S136V, E140C, E140A, 1149C, N151Q, K152L, L153F, D155T, T162I, K169E, N212S, V238F, I239L, H241N, S264R, T268D, T268E, V280P, T297C, L299F, M300R, M305N, L312I, C316A, N322T, H357R, K360Q, K396R, K397S, Y421F, H430Y, A447N, A447D, A449S, A449V, V450I, K476L, R485K, V492A, Y495F, L507I, H512N, L585K, S589T, T595K and Q603K, relative to the sequence of SEQ ID NO: 39.

17. The non-naturally occurring polynucleotide of claim 12 , wherein the amino acid sequence comprises at least 4 mutations selected from S41V, L43S, V81E, V81P, D83S, V85L, P125S, Q126S, Q131R, Q131T, S136V, E140C, E140A, 1149C, N151Q, K152L, L153F, D155T, T162I, K169E, N212S, V238F, 1239L, H241N, S264R, T268D, T268E, V280P, T297C, L299F, M300R, M305N, L312I, C316A, N322T, H357R, K360Q, K396R, K397S, Y421F, H430Y, A447N, A447D, A449S, A449V, V450I, K476L, R485K, V492A, Y495F, L507I, H512N, L585K, S589T, T595K and Q603K, relative to the sequence of SEQ ID NO: 39.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2021
From: MINSHULL, JEREMY; GOVINDARAJAN, SRIDHAR; LEE, MAGGIE
To: DNA TWOPOINTO INC.
Reel/Frame 056467/0784 →
Continuity (5)
Continuation 16842707 · Apr 7, 2020
Provisional Application 62978862 · Feb 20, 2020
Provisional Application 62873346 · Jul 12, 2019
Provisional Application 62831103 · Apr 8, 2019
Related Publication 20210292719A1 · Sep 23, 2021
References Cited (105)
US 7932088B1 · Adams et al. · 2011 [cited by applicant]
US 9670503B2 · Craig · 2017 [cited by applicant]
US 11060086B2 · Minshull et al. · 2021 [cited by applicant]
US 11060098B2 · Minshull et al. · 2021 [cited by applicant]
US 11060109B2 · Minshull et al. · 2021 [cited by applicant]
US 11401521B2 · Govindarajan et al. · 2022 [cited by applicant]
US 20080263730A1 · Anderson · 2008 [cited by applicant]
US 20100129914A1 · Koga et al. · 2010 [cited by applicant]
US 20110045532A1 · Kawakami et al. · 2011 [cited by applicant]
US 20120027847A1 · Kusk · 2012 [cited by applicant]
US 20170101629A1 · Minshull et al. · 2017 [cited by applicant]
US 20200318107A1 · Minshull et al. · 2020 [cited by applicant]
US 20200318121A1 · Minshull et al. · 2020 [cited by applicant]
US 20200318135A1 · Minshull et al. · 2020 [cited by applicant]
US 20210292773A1 · Minshull et al. · 2021 [cited by applicant]
US 20210324408A1 · Minshull et al. · 2021 [cited by applicant]
WO WO2010143698A1 · 2010 [cited by applicant]
WO WO2013155572A1 · 2013 [cited by applicant]
WO WO17062668 · 2017 [cited by examiner]
WO WO2017062668A2 · 2017 [cited by applicant]
WO WO2020210236A1 · 2020 [cited by applicant]
WO WO2020210237A1 · 2020 [cited by applicant]
WO WO2020210239A1 · 2020 [cited by applicant]
Fritz et al. (bioRxiv, 2017, pp. 1-44. [cited by examiner]
Johnson et al., Mol. Genet. Genomics, 2014, 289: 895-902. [cited by examiner]
Yusa et al., Microbiology Spectrum, 2014, 3: 1-16. [cited by examiner]
Wu, Genetica, 2011, 139: 149-154. [cited by examiner]
Bouallegue, Genome Biol. Evol., 2017, 9: 323-339. [cited by examiner]
Fritz_entry version 2, 2018. [cited by examiner]
Belancio et al., “Mammalian non-LTR retrotransposons: For better or worse, in sickness and in health,” Genome Research, 18;343-358, (2008). [cited by applicant]
Bonizzoni et al., “Highly similar piggyBactransposase-like sequences from various [cited by applicant]
Bouallegue, et al., “Molecular Evolution of piggyBac Superfamily: From Selfishness to Domestication,” Genome Biol. Evol. 9(2):323-339, (Jan. 12, 2017). [cited by applicant]
Daimon et al., “Recent transposition of yabusame, a novel piggyBac-like transposable element in the genome of the silkworm, [cited by applicant]
Databse RefSeq XP 013190765, online, NCBI, “Predicted: piggyBac transposable element-derived protein 4-like {Amyelois transittela},” Aug. 6, 2015. [cited by applicant]
Deininger et al., Alu Repeats and Human Disease, Molecular Genetics and Metabolism, 67, 183-193, (1999). [cited by applicant]
Doherty et al., “Hyperactive piggyBac Gene Transfer in Human Cells and In Vivo,” Human Gene Therapy, 23:311-320, (2012). [cited by applicant]
Genbank Accession No. NW_0133535463.1, Anyelois transitella strain UIUC subculture of SPIRL-1966 unplaced genomic scaffold, ASM118610v1 Atra_scaffold_0159, whole genome shotgun sequence, 1 page, (Aug. 2015). [cited by applicant]
Genbank Accession No. XM_133335311, Predicted: Amyelois transitella piggyBac transposable element-derived protein 4-like (LOC106135111), mRNA, 2 pages, (Aug. 2015). [cited by applicant]
GenBank: : Accession No. ABD76335.1, “transposase [Heliothis virescens],” Direct Submission on Feb. 19, 2006, Entomology, Kansas State Univ, retrieved @: www.ncbi.nlm.nih.gov/protein/abd76335.1. [cited by applicant]
GenBank: : Accession No. PCG77621.1, “hypothetical protein B5V51_6758 [Heliothis virescens],” Direct Submission on Sep. 2, 2017, Department of Entomology, Univ. of Maryland; Retrieved on Dec. 8, 2020 @: www.ncbi.nlm.nih… [cited by applicant]
GenBank: BAF64515.1, Transposase [ [cited by applicant]
Guilliam, et al., “Molecular basis for PrimPol recruitment to repliation forks by RPA,” Nature Communications, vol. 8, No. 551, pp. 1014, (2017). [cited by applicant]
Handler et al., “The piggyBac transposon mediates germ-line transformation in the Oriental fruit fly and closely related elements exist in its genome,” Insect Molecular Biology, 9(6):605-612, (2000). [cited by applicant]
Hikosaka et. al., “Evolution of the Xenopus piggyBac Transposon Family TxpB: Domesticated and Untamed Strategies of Transposon Subfamilies,” Mol. Biol. Evol., 24(12):2648-2656, (2007). [Retrieved from the Internet Apr. … [cited by applicant]
Kasahara, et al., “The medaka draft genome and instights into vertebrate genome evolution,” Nature, vol. 447, pp. 714-719, (2007). [cited by applicant]
Kawakami, et al., “Identification of a functional transposase of the Tol2 element, an Ac-llike element from the Japanese medaka fish, and its transposition in the zebrafish germ lineage,” PNAS, vol. 97, No. 21, pp. 1140… [cited by applicant]
Le Rouzic et al., “Reversible introduction of transgene in natural populations of insects,” Insect Molecular Biology, 15(2), 227-234, (2006). [cited by applicant]
Li, et al., “piggyBac internal sequences are necessary for efficient transformation of target genomes,” Insect Molecular Biology, 14(1), pp. 17-30, (2005). [cited by applicant]
Luo et al., “A new active piggyBac-like element in Aphis gossypii,” Insect Science, 18:652-662, (2011). [cited by applicant]
Luo et al., “Molecular characterization of the piggyBac-like element, a candidate marker for phylogenetic research of Chilo suppressalis (Walker) in China,” BMC Molecular Biology, 15:28, 12 pages, (2014). [cited by applicant]
Mitra, et al., “Functional characterization of piggyBat from the bat [cited by applicant]
Muñoz-López et al., “DNA Transposons: Nature and Applications in Genomics,” Current Genomics, 11:115-128, (2010). [cited by applicant]
NCBI Reference Sequence: XP_023815209.1, piggyBac transposable element-dirived protein 4-like [Oryzias latipes], BioProject: PRJNA193868, Feb. 15, 2018, retrieved @: www.ncbi.nlm.nih.gov/protein/XP_023815209.1. [cited by applicant]
NCBI Reference Sequence: XP_030017403.1, piggyBac transposable element-dirived protein 4-like [Sphaeramia orbicularis], BioProject: PRJNA556027, Aug. 2, 2019, retrieved @: www.ncbi.nlm.nih.gov/protein/XP_030017403.1. [cited by applicant]
NCBI References Sequence: XP_026724774.1, piggyBac transposable element-dirived protein 4-like [Trichoplusia ni], BioProject: PRJNA497582, Oct. 25, 2018, retrieved @: www.ncbi.nlm.nih.gov/protein/XP_026724774.1. [cited by applicant]
Sarkar et. al., “Molecular evolutionary analysis of widespread piggyBac transposon family and related ‘domesticated’ sequences,” Mol Gen Genomics, 270(2):173-180, (2003). [cited by applicant]
Sequence Alignment of SDQ ID No. 108 from U.S. Patent Application 2020-0318121; Seq ID 15 Sequence Search Conducted on Dec. 26, 2020, 1 page. [cited by applicant]
Sequence Alignment of SDQ ID No. 108 from U.S. Patent Application 2020-0318121; Seq ID 16, Sequence Search Conducted on Dec. 26, 2020, 1 page. [cited by applicant]
Sequence Alignment of SDQ ID No. 256 from U.S. Patent Application 2020-0318135; Seq ID 15, Sequence Search Conducted on Dec. 26, 2020, 1 page. [cited by applicant]
Sequence Alignment of SDQ ID No. 256 from U.S. Patent Application 2020-0318135; Sequence Search Conducted on Dec. 26, 2020, 1 page. [cited by applicant]
Sequence Alignment of SEQ ID No. 781 with CP020674s3, Sequence search conducted Sep. 28, 2021, 6 pages, (2021). [cited by applicant]
Sequence Alignment of SEQ ID No. 782 with A0A3Q2ZEU4 Kryma, search conducted Dec. 14, 2021; submitted to UniProtKB on (Jan. 2019). [cited by applicant]
Sequence Alignment of SEQ ID No. 7 with SEQ ID No. 55960 of U.S. Patent Application 2008/0263730; Sequence Search Conducted on Sep. 18, 2020, 1 page. [cited by applicant]
Sequence Alignment of SEQ ID No. 8 with SEQ ID No. 55960 of U.S. Patent Application 2008/0263730; Sequence Search Conducted on Sep. 18, 2020, 1 page. [cited by applicant]
UnitProt Submission A0A2A4JOM2_Helvi, Uncharacterized protein from [cited by applicant]
UnitProt Submission A0A2A4K028_HELVI, [cited by applicant]
UnitProt Submission A0A3B3INT3_ORYLA [cited by applicant]
Wang et al., “Large diversity of the piggyBac-like elements in the genome of Tribolium castaneum,” Insect Biochem Mol Biol, 38(4):490-498, doi: 10.1016/j.ibmb.2007.04.012, (2008). [cited by applicant]
Wang et al., “piggyBac-like elements in the tobacco budworm, [cited by applicant]
Wu et al., “An active piggyBac-like element in Macdunnoughia crassisigna,” Insect Science, 15:521-528, (2008). [cited by applicant]
Wu et.al., “Cloning and characterization of piggyBac-like elements in lepidopteran insects,” Genetica, 139:149-154, (Jan. 6, 2011). [cited by applicant]
Xu et al., “Identification and characterization of piggyBac-like elements in the genome of domesticated silkworm, [cited by applicant]
Zimowska et al., “Highly conserved piggyBac elements in noctuid species of Lepidoptera,” Insect Biochemistry and Molecular Biology, 36:421-428, (2006). [cited by applicant]
EP 20787187.0 Extended European Search Report mailed Dec. 13, 2022. [cited by applicant]
EP 20788191.5 Extended European Search Report mailed Dec. 9, 2022. [cited by applicant]
EP20788172.3 Extended European Search Report mailed Dec. 22, 2022. [cited by applicant]
NCBI References Sequence: XP 013190765.1, Predicted: piggyBac transposable element-derived protein 4-like [Amyelois transitella], BioProject: PRJNA292025, Aug. 6, 2015, retrieved @:www.ncbi.nlm.nih.gov/protein/XP_013190… [cited by applicant]
NCBI References Sequence: XP 013197997.1; Predicted: piggyBac transposable element-derived protein 4-like [Amyelois transitella], BioProject: PRJNA292025, Aug. 6, 2015, retrieved @:www.ncbi.nlm.nih.gov/protein/XP_031397… [cited by applicant]
U.S. Appl. No. 16/842,707, Non-Final Office Action mailed Dec. 31, 2020. [cited by applicant]
U.S. Appl. No. 16/842,707, Notice of Allowance mailed Mar. 22, 2021. [cited by applicant]
U.S. Appl. No. 16/842,707, Requirement for Restriction/Election mailed Oct. 9, 2020. [cited by applicant]
U.S. Appl. No. 16/842,709, Non-Final Office Action mailed Jan. 6, 2021. [cited by applicant]
U.S. Appl. No. 16/842,709, Notice of Allowance mailed Apr. 13, 2021. [cited by applicant]
U.S. Appl. No. 16/842,709, Requirement for Restriction/Election mailed Sep. 28, 2020. [cited by applicant]
U.S. Appl. No. 16/842,719, Non-Final Office Action mailed Dec. 22, 2020. [cited by applicant]
U.S. Appl. No. 16/842,719, Notice of Allowance mailed Apr. 6, 2021. [cited by applicant]
U.S. Appl. No. 17/339,597, Non-Final Office Action mailed Dec. 21, 2021. [cited by applicant]
U.S. Appl. No. 17/339,597, Notice of Allowance mailed Mar. 23, 2022. [cited by applicant]
U.S. Appl. No. 17/339,597, Requirement for Restriction/Election mailed Oct. 1, 2021. [cited by applicant]
U.S. Appl. No. 17/339,617, Non-Final Office Action mailed Jan. 5, 2022. [cited by applicant]
U.S. Appl. No. 17/339,617, Notice of Allowance mailed Mar. 2, 2022. [cited by applicant]
U.S. Appl. No. 17/339,617, Requirement for Restriction/Election mailed Oct. 7, 2021. [cited by applicant]
U.S. Appl. No. 16/842,719, Requirement for Restriction/Election mailed Jul. 17, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/027077, Invitation To Pay Additional Fees mailed Jul. 9, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/027077, PCT International Preliminary Report on Patentability mailed Sep. 28, 2021. [cited by applicant]
WIPO Application No. PCT/US2020/027077, PCT International Search Report and Written Opinion of the International Searching Authority mailed Sep. 4, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/027078, Invitation To Pay Additional Fees mailed Jul. 9, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/027078, PCT International Preliminary Report on Patentability mailed Sep. 28, 2021. [cited by applicant]
WIPO Application No. PCT/US2020/027078, PCT International Search Report and Written Opinion of the International Searching Authority mailed Sep. 4, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/027080, Invitation To Pay Additional Fees mailed Jul. 14, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/027080, PCT International Preliminary Report on Patentability mailed Sep. 28, 2021. [cited by applicant]
WIPO Application No. PCT/US2020/027080, PCT International Search Report and Written Opinion of the International Searching Authority mailed Sep. 4, 2020. [cited by applicant]
Skipper et al., “DNA transposon-based gene vehicles—scenes from an evolutionary drive,” Journal of Biomedical Science, 20:92, (2013). [cited by applicant]
MY P12021003499 Search Report mailed May 13, 2024. [cited by applicant]
MY P12021003506 Search Report mailed Apr. 30, 2024. [cited by applicant]